United Health Products Inc (UEEC)

[rayinbrooklyn65]

UEEC: Well, the next major step is acquiring approval by the FDA for use of HemoStyp® as a hemostatic agent for use in surgical procedures. Once that occurs, which I believe to be all but a done deal due to the restructuring of United Health Products (UHP) executive leadership from a CEO who specializes in the medical field, who was utilized to shepherd the company's product through the complex clinical trials, to the new CEO who specializes in marketing pharmaceutical products.

United Health Products Bolsters Management Team and Issues Chairman’s Letter to Shareholders

United Health Products, Inc. (OTC: UEEC), ("UHP" or the "Company"), developer, manufacturer and marketer of HemoStyp®, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent, today announced the appointment of John Phillips to the newly created position of Vice President, Marketing & Commercial Strategy, effective December 15, 2020.

John brings over 30 years of product commercialization and consulting experience with both pharma and medical device portfolios including direct experience with hemostatic and wound care products. In his new role, John will have primary responsibility for developing and executing UHP’s commercial strategies, including potential distribution partnerships, for the Class III surgical, Emergency Medicine, Hemodialysis and other markets, on a global basis.

Since 2019 John has been advising medical device and pharma clients as founding partner of Orrizonte Partners. From 2013-19, John held senior consulting positions with IQVIA and Deloitte Transaction & Business Analytics advising life sciences clients (including UHP) regarding market assessment and commercialization strategies. From 1998-2013, John worked in business strategy and commercial development roles with various companies including Johnson & Johnson’s Pharma and Medical Devices divisions where he led the team that developed the initial Marketing and Launch Excellence Framework, a cross-functional commercial planning process.

As UHP prepares for the anticipated receipt of its FDA PMA and the transition to a commercialization phase, John’s commercial expertise, industry relationships and leadership experience will make a significant contribution to driving revenue growth and market penetration across the Company’s priority markets. With this addition, the UHP senior management team now holds the necessary capabilities across the regulatory, R&D, manufacturing, logistics and commercial disciplines to build out a profitable enterprise.

UHP’s Chairman, Doug Beplate, commented: "John’s capabilities and experience are a perfect fit with our business strategy. He knows our HemoStyp technology and the industry very well and shares our vision of introducing a new solution that will reduce overall costs of care and improve patient outcomes. Moreover, as an industry insider, he is well positioned to offer guidance on any commercial partnership or corporate sale proposals. We are extremely pleased to fill this remaining gap in our management and leadership team with such a talented individual."

Source: Yahoo Finance. December 15, 2020

The prior CEO, now remaining on the Board of Directors at UHP, is Douglas Beplate. Mr. Beplate served as UHP CEO from November 2014 to December 2020 and served as Chief Operating Officer starting November 2013. He became a director and Chairman of the Board in 2015. Mr. Beplate has supported the development of hemostatic technologies since 2003 and has been working on the development of HemoStyp gauze since 2010. From 1996 to 2007, Mr. Beplate was founder and President of Emergency Filtration Products, Inc. (“EFP”) where his responsibilities included product design, research and development, patent work and production. During his time at EFP, he was awarded a grant through California State University San Bernardino for development of nanotechnology for the U.S. government and military sector. Prior to his position at EFP he was a consultant to various medical products firms where he was involved in research and development, and product design.

The next steps, after receiving FDA approval, would be bifurcated into one of two options:

1. UHP ramping up internal production protocols for the commercialization of HemoStyp® by developing supply chain logistics for the manufacture and distribution of this clotting agent to take advantage of opportunities within the $5.8 billion global market demand; or, as a more likely scenario,

2. Due to its lack of capitalization, UHP would begin negotiations with a major pharmaceutical company with existent global production capabilities and distribution logistics to structure a buyout of the company at a fair market value given the PROVEN enhancements HemoStyp® would bring to the medical community. This most likely suitor for UHP would be Johnson and Johnson Pharmaceutical, the manufacturer of SURGICEL®, another hemostatic protocol and the most direct competitor for UHP's blood clotting treatment protocol.

Either of the aforementioned business propositions, in and of themself, involve complex legal, financial and business transactions and would be broken down into many steps in the process to coming to fruition.

While it is admittedly frustrating observing the share price of UEEC trade ostensibly sideways for the past three weeks, my suggestion is to STAY THE COURSE and disregard the current but TEMPORARY external forces currently roiling the markets as they will exert only a minimum impact on the share price of UEEC because the fundamentals of this company, as previously enumerated are too positive and so voluminous as to keep this stock trading below $5.00 per share for very long.

Rainy:

what are the 10 steps and the timelines?...If we are at 4, then when the heck do we get to 10? this is getting ridiculous